Group 1 - The company held its third extraordinary general meeting of shareholders on December 29, 2025, in Shanghai, with no resolutions being rejected [2] - The meeting was convened by the board of directors and conducted in accordance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [2][3] - The meeting was attended by 7 out of 8 current directors, with the board secretary and other executives present, while one independent director was absent due to work commitments [3] Group 2 - A key resolution passed during the meeting was regarding the change of certain fundraising projects and the acquisition of equity in Suzhou Jiesibai Medical Technology Co., Ltd., which was approved [4] - The voting for the resolutions was conducted as ordinary resolutions, requiring more than half of the voting shares represented at the meeting to pass [5] Group 3 - The company signed a tripartite supervision agreement for the storage of raised funds, ensuring effective management and protection of investor rights [7][11] - The company was approved to publicly issue 41.4142 million shares at a price of RMB 36.22 per share, raising a total of RMB 1.5 billion, with a net amount of RMB 1.382 billion after deducting issuance costs [8][9] - A special account for the raised funds was established, which is exclusively for the storage and use of funds related to the acquisition and capital increase project [10][12] Group 4 - The tripartite agreement involves the company, China Agricultural Bank, and Huatai United Securities, outlining the management and supervision of the raised funds [12] - The agreement stipulates that any withdrawal exceeding RMB 50 million or 20% of the net raised funds must be reported to the supervising party [14] - The agreement will remain effective until all funds are fully utilized and the account is legally closed [15]

Core Viewpoint - Weigao Orthopedics announced the convening of its third extraordinary shareholders' meeting on December 29, 2025, in Shanghai to review key proposals [1] Group 1 - The company will discuss the proposal to change part of the fundraising projects and to acquire equity in Suzhou Jiesbai Medical Technology Co., Ltd., along with plans for capital increase [1] - The election of Mr. Li Jinqiu as a non-independent director of the third board of directors will also be on the agenda [1]

证券代码：688161 证券简称：威高骨科 公告编号：2025-051 山东威高骨科材料股份有限公司 关于签订募集资金专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会审核同意，并根据中国证券监督管 理委员会出具证监许可〔2021〕1876 号同意注册文件，公司获准向社会公众公 开发行人民币普通股（A 股）股票 4,141.42 万股，每股面值人民币 1.00 元，发 行价格为每股人民币 36.22 元，共计募集资金人民币 150,002.23 万元。扣除与发 行有关的费用人民币 11,773.74 万元后，募集资金净额为人民币 138,228.49 万元。 上述募集资金到位情况经大华会计师事务所（特殊普通合伙）审验，并由其出具 《验资报告》（大华验字[2021]000392 号）。 公司对募集资金采取了专户存储制度，上述募集资金到账后，已存放于募集 资金专户，公司按规定与保荐机构、募集资金专户监管银行签署《募集资金专户 存储三方监管协议》 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-052 山东威高骨科材料股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 29 日 （二） 股东会召开的地点：上海市闵行区方亭路 499 号威高云行智创园公司会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 53 | | --- | --- | | 普通股股东人数 | 53 | | 2、出席会议的股东所持有的表决权数量 | 335,834,687 | | 普通股股东所持有表决权数量 | 335,834,687 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 83.9587 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 83.9587 | ...

北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2025 年第三次临时股东会的 法律意见书 二〇二五年十二月 法律意见书 致：山东威高骨科材料股份有限公司 根据中国证监会发布的《上市公司股东会规则》（下称"《股东会规则》"）的 有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受山东威高骨科 材料股份有限公司（下称"公司"）的委托，指派律师出席公司 2025 年第三次临 时股东会（下称"本次股东会"），并就本次股东会的召集和召开程序、召集人资 格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 诚实信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准 确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并承担相应法律责任。 一、本次股东会的召集和召开程序 北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2 ...

证券代码：688161 证券简称：威高骨科 山东威高骨科材料股份有限公司 2025 年第三次临时股东会 会议资料 二零二五年十二月 | 2025 年第三次临时股东会会议须知 … | | --- | | 2025 年第三次临时股东会会议议程 . | | 2025 年第三次临时股东会会议议案 . | | 关于变更部分募投项目暨收购苏州杰思拜尔医疗科技有限公司股权并对其增 | | 资的议案 | | 关于补选公司第三届董事会非独立董事的议案 | 山东威高骨科材料股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《山东威高骨科材料股份有限公司章程》等相关规定，山东威高骨科材料股份 有限公司（以下简称"公司"）特制定 2025 年第三次临时股东会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议人员的身份进行必要的核对工作，请被核对者给予配合。 出席会议的股东及股东代理人须在会议召开前 30 分钟到会议 ...

Group 1 - The board of directors of Shandong Weigao Orthopedic Materials Co., Ltd. held its 18th meeting of the third session on December 17, 2025, with all 8 directors present, complying with relevant laws and regulations [1][2]. - The board approved a proposal to establish a special account for raised funds and sign a tripartite supervision agreement with Agricultural Bank of China and Huatai United Securities, ensuring that the funds will only be used for designated investment projects [1][2]. - The decision is deemed legal and compliant with the company's articles of association, aimed at standardizing the management and use of raised funds without harming the interests of the company and its shareholders [1].

Group 1 - The core point of the article is that Weigao Orthopedics announced the convening of its third board meeting to discuss the establishment of a special fundraising account and the signing of a tripartite supervision agreement for fundraising [1] - For the year 2024, Weigao Orthopedics' revenue composition is 99.85% from the medical device manufacturing industry and 0.15% from other businesses [1] - As of the report, Weigao Orthopedics has a market capitalization of 11.1 billion yuan [1]

证券代码：688161 证券简称：威高骨科 公告编号：2025-050 山东威高骨科材料股份有限公司董事会 2025 年 12 月 18 日 山东威高骨科材料股份有限公司（以下简称"公司"）第三届董事会第十八 次会议于 2025 年 12 月 17 日以书面审议的方式召开。本次会议应出席董事 8 人， 实际出席董事 8 人。本次会议的出席人数、召开表决程序、议事内容均符合《中 华人民共和国公司法》《公司章程》等有关规定。 二、董事会会议审议情况 1、审议通过《关于设立募集资金专项账户并签订募集资金三方监管协议的 议案》 公司董事会认为：公司拟与中国农业银行股份有限公司威海高技术产业开发 区支行及保荐机构华泰联合证券有限责任公司签署募集资金三方监管协议，并设 立募集资金专项账户，该专户仅用于募集资金投资项目中募集资金的存储和使用， 不得用作其他用途。该事项符合相关法律法规及《公司章程》的规定，决策程序 合法合规，有利于规范募集资金管理和使用，不存在损害公司及股东利益的情形。 表决结果：8 票同意，0 票反对，0 票弃权。 特此公告。 山东威高骨科材料股份有限公司 第三届董事会第十八次会议决议公告 本公司董事会及 ...

Core Points - The Sci-Tech Innovation 50 Index opened with adjustments on December 12, then fluctuated upwards, closing significantly higher at 1348.88 points, with an increase of 1.74% and a trading range of 2.83%, totaling a transaction volume of approximately 83.87 billion yuan [1] - The Sci-Tech Comprehensive Index also rose by 1.77%, closing at 1611.93 points, with a total transaction volume of about 248 billion yuan. Among the 595 stocks in the Sci-Tech board, most rose while low-priced stocks showed mixed performance [2] Stock Performance - The top performer was Jingfeng Mingyuan, which hit the daily limit, while Moer Thread saw the largest decline at 13.41% [3] Transaction Volume - Cambrian Technology led in transaction volume with 12.5 billion yuan, while Conglin Technology had the lowest at 465 million yuan [4] Turnover Rate - Moer Thread had the highest turnover rate at 42.26%, while Weigao Orthopedics had the lowest at 0.2% [5]